Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure ethiology and correlates to clinical variables

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 303, Issue 3, 2012, Pages 368-376

  Montó, Fermí ^a   Oliver, Eduardo ^a   Vicente, Diana ^a   Rueda, Joaquín ^b   Agüero, Jaime ^b   Almenar, Luis ^b   Ivorra, Maria Dolores ^a   Barettino, Domingo ^c   D'Ocon, Pilar ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

G protein coupled receptor kinases

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 5;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART RIGHT VENTRICLE; HUMAN; ISCHEMIC CARDIOMYOPATHY; LEFT VENTRICULAR END DIASTOLIC DIAMETER; LEFT VENTRICULAR END SYSTOLIC DIAMETER; MALE; NONISCHEMIC CARDIOMYOPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANALYSIS OF VARIANCE; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASES; GENOTYPE; HEART FAILURE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PHENOTYPE; RECEPTORS, ADRENERGIC; RNA, MESSENGER; SPAIN; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84864542754     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01061.2011     Document Type: Article

References (45)

1. Aguero J, Almenar L, D'Ocon P, Oliver E, Monto F, Rueda J, Vicente D, Martínez-Dolz L, Salvador A. Myocardial and peripheral lympho-cytic transcriptomic dissociation of beta-adrenoceptors and G protein-coupled receptor kinases in heart transplantation. J Heart Lung Transplant 28: 1166-1171, 2009.
2. Aguero J, Almenar Monto FL, Oliver E, Sanchez-Lazaro I, Vicente D, Martinez-Dolz L, D'Ocon P, Rueda J, Salvador A. Myocardial G-protein coupled kinase expression associates with functional parameters and clinical severity in advanced heart failure. J Card Fail 18: 53-61, 2012.
3. ALLHAT. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-low-ering treatment to prevent heart attack trial. ALLHAT Collaborative Research Group. JAMA 283: 1967-1975, 2000.
4. Arnett DK, Devereux RB, Kitzman D, Oberman A, Hopkins P, Atwood L, Dewan A, Rao DC. Linkage of left ventricular contractility to chromosome 11 in humans: The HyperGEN Study. Hypertension 38: 767-772, 2001.
5. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 92: 2737-2745, 1993.
6. Brattelid T, Winer LH, Levy FO, Liestøl K, Sejersted OM, Andersson KB. Reference gene alternatives to Gapdh in rodent and human heart failure gene expression studies. BMC Mol Biol 23: 11-22, 2010.
7. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharm Sci 100: 323-337, 2006.
8. Brodde OE, Bruck H, Leineweber K, Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 96: 528-538, 2001.
9. Dorn mythology: Gprotein GWGRK.Receptor kinases in cardiovascular disease. J Mol Med 87: 455-463, 2009.
10. Dzimiri N, Basco C, Moorji A, Afrane B, Al Halees Z. Characterization of lymphocyte beta 2- adrenoceptor signalling in patients with left ventricular volume overload disease. Clin Exp Pharmacol Physiol 29: 181-188, 2002.
11. Dzimiri N, Muiya P, Andres E, Al Halees Z. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol 489: 167-177, 2004.
12. Engelhardt S, Bohm M, Erdmann E, Lohse MJ. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 27: 146-154, 1996.
13. Eschenhagen T. Beta-adrenergic signalling in heart failure-adapt or die. Nat Med 14: 485-487, 2008.
14. Hata JA, Koch WJ. Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease. Mol Interv 3: 264-272, 2003.
15. Hendriks-Balk MC, Peters SL, Michel MC, Alewijnse AE. Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. Eur J Pharmacol 585: 278-291, 2008.
16. Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, O'Connel TD. An alpha1A-adrenergic- extracellular signal-regulated ki-nase survival signalling pathway in cardiac myocytes. Circulation 115: 763-772, 2007.
17. Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, Leosco D, Trimarco B, Koch WJ. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J 26: 1752-1758, 2005.
18. Jensen BC, O'Connell TD, Simpson PC. Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol 51: 518-528, 2011.
19. Jensen BC, Swigart PM, De Marco T, Hoopes C, Simpson PC. Alpha1-adrenergic receptor subtypes in nonfailing and failing human myocardium. Circ Heart Fail 2: 654-663, 2009.
20. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, Spertus JA, Koch WJ, Kardia SL, Dorn GW. A GRK5 polymorphism that inhibits betaadrenergic receptor signaling is protective in heart failure. Nat Med 14: 510-517, 2008.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-delta delta C(T)] method. Methods 25: 402-408, 2001.
22. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signalling in heart failure? Circ Res 93: 896-906, 2003.
23. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346: 1357-1365, 2002.
24. Metaye T, Gibelin H, Perdrisot R, Kraimps JL. Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal 17: 917-928, 2005.
25. Moniotte S, Vaerman JL, Kockx MM, Larrouy D, Langin D, Noirhomme Balligand JLP. Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol 33: 2121-2133, 2001.
26. Noor N, Patel CB, Rockman HA. β-Arrestin: a signalling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol 51: 534-541, 2011.
27. O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turn-bull L, Tecott LH, Baker AJ, Foster E, Grossman W, Simpson PC. Alpha1-adrenergic receptors prevents a maladaptive cardiac response to pressure overload. J Clin Invest 116: 1005-1015, 2006.
28. Oliver E, Rovira E, Monto F, Valldecabres C, Julve R, Muedra V, Ruiz N, Barettino D, D'Ocon P Beta-adrenoceptor and GRK3 expression in human lymphocytes is related to blood pressure and urinary albumin excretion. J Hypertens 28: 1281-1289, 2010.
29. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signalling in chronic heart failure. J Mol Cell Cardiol 33: 887-905, 2001.
30. Rengo G, Lymperopoulus A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 50: 785-792, 2011.
31. Segura V, Flacco N, Oliver E, Barettino D, D'Ocon P, Ivorra MD. Alpha1-adrenoceptors in the rat cerebral cortex: new insights into the characterization of alpha1L- and alpha1D-adrenoceptors. Eur J Pharmacol 641: 41-48, 2010.
32. Skomedal T, Borthne K, Aass H, Geiran O, Osnes JB. Comparison between alpha-1 adrenoceptormediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 280: 721-729, 1997.
33. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54: 1747-1762, 2009.
34. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrener-gic receptors in the failing human heart. Circulation 87: 454-463, 1993.
35. Ungerer M, Parruti G, Bohm M, Puzicha M, DeBlasi A, Erdmann E, Lohse MJ. Expression of betaarrestins and beta-adrenergic receptor kinases in the failing human heart. Circ Res 74: 206-213, 1994.
36. Vanderheyden M, Mullens W, Delrue L, Goethals M, Verstreken S, Wijns W, de Bruyne B, Bartunek J. Endomyocardial upregulation of beta1 adrenoceptor gene expression and myocardial contractile reserve following cardiac resynchronization therapy. J Card Fail 14: 172-178, 2008.
37. Vinge LE, Oie E, Andersson Y, Grogaard HK, Andersen G, Attra-madal H. Myocardial distribution and regulation of GRK and β-arrestin isoforms in congestive heart failure in rats. Am J Physiol Heart Circ Physiol 281: H2490-H2499, 2001.
38. Vinge LE, von Lueder TG, Aasum E, Qvigstad E, Gravning JA, How How OJ OJ, Edvardsen T, Bjørnerheim R, Ahmed MS, Mikkelsen BW, Oie E, Attramadal T, Skomedal T, Smiseth OA, Koch WJ, Larsen TS, Attramadal H. Cardiac-restricted expression of the carboxyl-terminal fragment of GRK3 uncovers distinct functions of GRK3 in regulation of cardiac contractility and growth: GRK3 controls cardiac alpha1-adrenergic receptor responsiveness. J Biol Chem 283: 10601-10610, 2008.
39. Wang GY, Yeh CC, Jensen BC, Mann MJ, Simpson PC, Baker AJ. Heart failure switches the RV α 1 -adrenergic inotropic response from negative to positive. Am J Physiol Heart Circ Physiol 298: H913-H920, 2010.
40. Woodcock EA. Roles of alpha1A- and alpha1B-adrenoceptors in heart: insights from studies of genetically modified mice. Clin Exp Pharmacol Physiol 34: 884-888, 2007.
41. Woodcock EA, Du XJ, Reichelt ME, Graham RM. Cardiac alpha 1-adrenergic drive in pathological remodeling. Cardiovasc Res 77: 452-462, 2008.
42. Xiang Y, Kobilka BK. Myocyte adrenoceptor signalling pathways. Science 300: 1530-1532, 2003.
43. Xiao RP, Zhu W, Zheng M, Chakir K, Bond R, Lakatta EG, Cheng H. Subtype-specific betaadrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 25: 358-365, 2004.
44. Xiao RP, Zhu W, Zheng M, Cao C, Zhang Y, Lakatta EG, Han Q. Subtype-specific alpha1- and beta-adrenoceptor signalling in the heart. Trends Pharmacol Sci 27: 330-337, 2006.
45. Zhu W, Zeng X, Zheng M, Xiao RP. The enigma of beta2-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly. Circ Res 97: 507-509, 2005.